Royalty Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	1,135	42.83	619.73	975.04	2,349	1,378	1,210
Other Operating Activities	1,853	2,101	1,398	1,060	-681.3	240.59	208.29
Operating Cash Flow	2,988	2,144	2,018	2,035	1,667	1,618	1,418
Operating Cash Flow Growth	39.36%	6.27%	-0.84%	22.04%	3.02%	14.10%	-
Capital Expenditures	-12.4	0	-18.6	0	-250	0	0
Acquisitions	0	0	0	0	-27.04	-24.17	-2
Change in Investments	-2,058.35	-1,029.42	-1,851.68	-2,759.32	-1,876.58	327.6	-1,585.71
Other Investing Activities	-2.04	-	-	-	-	-	-
Investing Cash Flow	-2,072.79	-1,029.42	-1,870.28	-2,759.32	-2,153.63	303.42	-1,587.71
Dividends Paid	-358.33	-333.32	-285.18	-397.84	-739.28	-814.36	-735.17
Share Issuance / Repurchase	-304.76	0	0	1,909	-4.27	0	0
Debt Issued / Paid	-1,001.6	-1.35	1,259	633.92	-294	-296.05	907
Other Financing Activities	-484.07	-610.19	-589.19	-657.65	-154.08	-268.69	-295.08
Financing Cash Flow	-2,148.75	-944.86	385.11	1,487	-1,191.63	-1,379.1	-123.25
Net Cash Flow	-1,233.74	169.7	532.37	762.48	-1,678.01	542.64	-292.65
Free Cash Flow	2,975	2,144	1,999	2,035	1,417	1,618	1,418
Free Cash Flow Growth	38.78%	7.26%	-1.75%	43.56%	-12.43%	14.10%	-
Free Cash Flow Margin	126.37%	95.83%	87.31%	95.87%	78.12%	90.16%	88.76%
Free Cash Flow Per Share	6.65	4.89	4.82	5.42	2.38	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).